ALBUTEROL SULFATE I

Albuterol Sulfate Inhalation Aerosol with HFA, NSN 6505015436562, is being procured under solicitation SPE2DP-26-T-3324 for delivery to Fort Bragg, North Carolina, with a strict 20-day delivery window following contract award. Each actuation delivers 108 mcg of albuterol sulfate (equivalent to 90 mcg of albuterol base) from an 8.5-gram canister containing 200 metered doses, supplied in single-unit packaging. The product must be stored at room temperature between 59°F and 77°F, must not be punctured or exposed to heat exceeding 120°F, and requires shaking prior to use. Labeling must include the national stock number, manufacturer, date of manufacture, expiration date, contract number, and lot number, with all packaging compliant with Medical Marking Standard No. 1, which replaces MIL-STD-129 for medical items. Shelf life is fixed at 24 months with no extensions permitted, and the item is classified as a Type I (Code M) medical product under DLA requirements. The contract imposes strict compliance with federal regulations including OSHA’s Hazard Communication Standard (29 CFR 1910.1200), requiring submission of GHS-compliant Safety Data Sheets and hazard labels prior to award, and mandates adherence to MIL-STD-2073-1E for packaging, preservation, and marking. The contracting officer must verify with the product specialist via EBS that the bidder, manufacturer, part number, and description meet FDA-regulated pharmaceutical standards. The solicitation applies Class Deviations 2025-00003 and 2025-00004 for simplified acquisition terms, and includes provisions for equal opportunity, combating human trafficking, employment eligibility verification, and sustainable procurement. Cybersecurity requirements under NIST SP 800-171 apply, mandating assessment and reporting of security controls to the Supplier Performance Risk System. Offers must be submitted electronically through DIBBS by May 18, 2026, with delivery FOB destination and inspection and acceptance occurring at the delivery point; invoicing must be processed through WAWF. Two manufacturers are identified: Teva Pharmaceuticals USA, Inc. with NDC 00093